Steroid class action certified on appeal
This article was originally published in The Tan Sheet
A California appellate court in Los Angeles sides with a class action certification attempt on appeal against GNC about steroid-containing supplements. The court's Jan. 21 1decision reverses a lower court's rejection of plaintiff Diego Martinez's class certification attempt. The previous rejection was based on an erroneous legal assumption - "that common issues did not predominate because class members would be required to individually litigate issues of causation and injury." Martinez attempted to certify a class of anyone who purchased products from GNC containing androstenediol in California between 2000 and 2004. He alleged damages based on GNC's deceptive conduct. GNC said it ceased selling so-called supplements with androstenediol, a schedule III controlled substance, in March 2004 (2"The Tan Sheet" Oct. 27, 2003)
You may also be interested in...
Androstenedione would be regulated as a controlled substance under legislation offered by Sen. Joseph Biden (D-Del.), and co-sponsored by Sens. Orrin Hatch (R-Utah), Tom Harkin (D-Iowa) and Charles Grassley (R-Iowa)
Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment.
Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.